Latest filing published 10 Mar 2026 for Acumen Pharmaceuticals, Inc., €3,331. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Derek M. Meisner (chief executive) discloses dealings in 2 companies, chiefly Acumen Pharmaceuticals, Inc. and X4 Pharmaceuticals, Inc. The record holds 22 filings, for trades running from 15 June 2021 to 6 March 2026.
Sales make up the whole of the open-market record (12 sales, €117k). The amount is not disclosed for 4 filings. Besides market trades, the filings include 7 share grants and 3 option exercises. 2026 to date brings no purchases and 4 sales.
The record was last updated on 10 March 2026 with an option exercise (€3,331) in Acumen Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations